Touchlight To Disrupt DNA Market With Synthetic Manufacturing

Touchlight Positions Itself To Meet Coming Demand For ‘100s of kilograms of DNA’

Touchlight has secured £42m ($60m) in funding to support efforts to triple its manufacturing capacity of synthetic DNA based on the company’s proprietary dbDNA platform – an enzyme made minimal linear DNA vector. The completed facility will have the capacity to produce 1kg of GMP DNA per month, enough for one billion COVID-19 vaccine doses.

• Source: Shutterstock

The Hampton, UK-based company has followed an unusual funding model to date. The latest financing of £42m was led by Bridford Investments and focused on “a network of ultra-high net worth individuals, family offices and specialist health care investors.”

Karen Fallen, CEO of Touchlight DNA Services, explained this was how the biotech had been financed from the beginning, following...

More from Manufacturing Focus

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.